Profil
Ryan Asay worked as a Director of Investor Relations at Bristol Myers Squibb Co. He then worked as the Head of Investor Relations at Spark Therapeutics, Inc. from 2017 to 2020.
From 2020 to 2024, he worked as the Vice President and Head of Corporate Affairs at Mirati Therapeutics, Inc.
Ehemalige bekannte Positionen von Ryan Asay
| Unternehmen | Position | Ende |
|---|---|---|
| MIRATI THERAPEUTICS | Corporate Officer/Principal | 23.01.2024 |
| SPARK THERAPEUTICS, INC. | Investor Relations Contact | 01.02.2020 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
Spark Therapeutics, Inc.
 Spark Therapeutics, Inc. BiotechnologyHealth Technology Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J. Fraser Wright, and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA. | Health Technology |
